TransCode Therapeutics is an RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. Our lead therapeutic candidate, that we believe has blockbuster potential, targets an RNA molecule which has been shown to be the driver of metastatic disease across multiple tumor types and has been validated pre-clinically by our scientific co-founders. Our initial FIH clinical study is intended to provide positive proof-of-mechanism for the TTX platform. We believe that demonstrating our ability to overcome the challenge of RNA delivery to genetic targets outside of the liver would represent a major step forward in unlocking therapeutic access to genetic targets involved in a range of cancers. We intend to build a broad and diverse pipeline of therapeutics and diagnostics with the potential to reach previously undruggable genetic targets that are well documented. We have a robust IP portfolio, experienced team, including a high profile and active scientific and medical advisory board, to execute our plan and we have demonstrated that we are highly capital efficient.